rTMS for MCI & Early Alzheimer's
Emerging therapy to enhance memory, cognition, and slow progression
Emerging therapy to enhance memory, cognition, and slow progression
Dementias or Major Neurocognitive Disorders can impair one's ability to live independently and meaningfully interact with loved ones. People with these diseases will generally progress from having mild cognitive impairment (MCI) to progressively worsening stages of dementia. MCI is not normal ageing - it occurs when there is an objective decline in cognitive abilities, but the person is still relatively independent. Alzheimer's disease is one of the most common dementias, a degenerative disease where cognition progressively declines over an average of 10 years.
The exact cause is not entirely known. However, most patients with MCI and early Alzheimer's have abnormal structural and functional changes within the brain. Genetic factors and environmental factors also play a role.
Unfortunately, there are no cures for these diseases, and no standard disease-modifying therapies are available. Current treatments focus on symptom management.
Several recently published systematic reviews have shown evidence that rTMS can enhance memory, concentration, and language skills.
rTMS may reduce the likelihood of MCI progressing to dementia.
It has also been shown to help with neurobehavioral symptoms such as anxiety, aggression, and sleep disturbances.
The treatment effects can be cumulative, leading to sustained cognitive benefits over time.
rTMS is currently being investigated as a promising treatment option in multiple clinical trials.
rTMS (Repetitive Transcranial Magnetic Stimulation) is a non-invasive treatment that uses magnetic fields to stimulate nerve cells in the brain. An electromagnetic coil placed against your scalp delivers painless magnetic pulses to specific brain regions.
By targeting areas of the brain associated with mood regulation, pain perception, addiction, or motor control, these magnetic pulses stimulate brain activity, promoting the healing process by encouraging the formation of new neural connections. This process, known as neuroplasticity, is the key to rTMS effectiveness.
Most people tolerate rTMS exceptionally well with minimal side effects. Any side effects are typically mild and tend to improve after each session. Common side effects may include headache, scalp discomfort, tingling of facial muscles, and lightheadedness. Serious side effects are very rare.
Common questions about rTMS treatment for mci & early alzheimer's.
Emerging research suggests that rTMS may help stabilize or improve cognitive function in patients with mild cognitive impairment (MCI) and early Alzheimer's disease. Several systematic reviews have found that rTMS can improve memory, language, and executive function in these populations. While rTMS is not a cure and does not address underlying pathology, it may help maintain cognitive function and potentially delay progression.
rTMS stimulates brain regions involved in memory and cognitive processing, particularly the dorsolateral prefrontal cortex and parietal cortex. This stimulation can enhance neuroplasticity - the brain's ability to form and strengthen neural connections. In MCI and early Alzheimer's, rTMS may help compensate for declining neural function by strengthening remaining healthy circuits and promoting new connections.
Clinical studies have documented improvements in episodic memory (recalling events and experiences), working memory (holding information in mind), language function (word-finding and verbal fluency), attention, and processing speed. Benefits vary by individual, and patients with milder impairment tend to show greater improvement. Quality of life and functional independence may also improve.
Treatment protocols typically involve 20-30 sessions over 4-6 weeks, with some protocols extending longer. Maintenance sessions are often recommended to sustain benefits, as the underlying condition is progressive. Some protocols target multiple brain regions across the treatment course. Response should be evaluated periodically using standardized cognitive assessments.
Current evidence most strongly supports rTMS for mild cognitive impairment and early-stage Alzheimer's disease, when there is still sufficient healthy brain tissue to respond to stimulation. Benefits may be more limited in moderate to severe stages. Candidacy should be determined through comprehensive evaluation. rTMS may also help manage behavioral symptoms such as anxiety, agitation, and sleep disturbances at any stage.
Yes, rTMS can be safely combined with cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine, the standard medications for Alzheimer's disease. There are no known drug interactions. Some research suggests that combining rTMS with pharmacotherapy may produce additive benefits. rTMS may also be combined with cognitive rehabilitation programs.
Book a free consultation to discuss how rTMS can help you.